News
Topline data were announced from two phase 3 studies evaluating tegoprazan in patients with gastroesophageal reflux disease (GERD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback